ASX News
Dale Gillham's weekly wrap: QBE surges despite ASIC action, how ASX's 9,000 mark may be achieved
With investors seemingly undeterred, the question is: could QBE now be a golden opportunity for your portfolio?
Corporate Spotlight
Neurizon Therapeutics Limited (ASX: NUZ) is a clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease.
View the full Corporate Spotlight
NUZ LATEST INTERVIEW WITH CEO & MD MICHAEL THURN
Latest Threads
See All Discussions
Corporate Spotlight
Timeline
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
| View More | |||||
Latest Videos
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
-0.005(2.70%) |
Mkt cap ! $88.54M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $22.63K | 127.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 47941 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 16270 | 1 |
View Market Depth
| Last trade - 15.56pm 13/12/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |
